Extrahepatic Cholangiocarcinoma: Understanding Your Pathology Report

by Jason Wasserman MD PhD FRCPC and Catherine Forse MD FRCPC
April 22, 2026

Extrahepatic cholangiocarcinoma is a type of cancer that starts in the bile ducts outside the liver — the small tubes that carry bile from the liver to the intestine, where bile helps digest fats. It includes tumors of the common bile duct and of the hepatic ducts near where they exit the liver. Tumors that arise at the junction of the right and left hepatic ducts are often called perihilar cholangiocarcinomas. For information on cancer that starts in the bile ducts within the liver, see our article on intrahepatic cholangiocarcinoma.

This article will help you understand the findings in your pathology report — what each term means and why it matters for your care.

What causes extrahepatic cholangiocarcinoma?

Extrahepatic cholangiocarcinoma is strongly associated with long-standing inflammation or bile ductal injury. Years of repeated injury, inflammation, and repair allow genetic changes to accumulate in the cells that line the ducts, and over time, a small number of these cells can begin to grow in an uncontrolled way.

Known risk factors include:

• Primary sclerosing cholangitis — A chronic disease that causes scarring and narrowing of the bile ducts and is the strongest known risk factor in North America and Europe.
• Bile duct cysts and congenital abnormalities — Structural differences in the bile ducts present from birth, such as choledochal cysts.
• Chronic bile duct blockage or infection — Long-standing obstruction from gallstones or recurrent bacterial cholangitis.
• Liver fluke infections — Parasitic infections with Opisthorchis viverrini or Clonorchis sinensis, most common in parts of Southeast Asia, that chronically injure the bile ducts.
• Other factors — Smoking, chronic pancreatitis, certain metabolic conditions, and rare occupational chemical exposures.

In many people, no clear cause is identified. Extrahepatic cholangiocarcinoma is most often diagnosed in people in their 60s or 70s and affects men and women at roughly equal rates.

What are the symptoms of extrahepatic cholangiocarcinoma?

Because extrahepatic cholangiocarcinomas block bile flow early, symptoms often appear while the tumor is still relatively small. The most common symptom is jaundice — yellowing of the skin and the whites of the eyes — which may worsen quickly or come and go.

Other symptoms can include itching, dark urine, pale or greasy stools, pain or discomfort in the right upper abdomen, fatigue, loss of appetite, unintentional weight loss, nausea, and vomiting. If an infection develops in the blocked bile ducts, a condition called cholangitis, fever and chills can occur and usually require urgent treatment.

How is the diagnosis made?

The diagnosis of extrahepatic cholangiocarcinoma is usually made using a combination of imaging, procedures that sample cells or tissue from inside the bile duct, and examination of the sample under the microscope by a pathologist. Imaging studies such as MRI with MRCP, CT, ultrasound, and PET scans are used to locate the tumor, measure its size, assess spread, and determine whether it can be removed with surgery. A typical imaging finding is a narrowing or thickening of the bile duct, with upstream ductal dilation.

Because bile ducts are small and difficult to reach, tissue is usually not obtained via standard surgical biopsy. Instead, samples are taken during endoscopic procedures, most often endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasound (EUS). During ERCP, a thin scope is passed through the mouth into the small intestine, and a tiny brush or forceps is advanced into the bile duct to collect cells or small pieces of tissue. These procedures also allow the placement of a stent to relieve bile duct blockage at the same time.

Under the microscope, most extrahepatic cholangiocarcinomas are adenocarcinomas, meaning they form abnormal gland-like structures. The glands are typically irregular and widely spaced, and are surrounded by dense scar tissue called desmoplastic stroma. The tumor cells often invade surrounding tissues, grow along nerves, and enter blood vessels and lymphatic channels — features that help explain the cancer’s ability to spread. Less common microscopic patterns include intestinal-type, mucinous, signet-ring cell, clear cell, and micropapillary carcinoma; rare cases show squamous, adenosquamous, or undifferentiated features. Pathologists also look for a precancerous change in the nearby bile duct lining called biliary intraepithelial neoplasia, which supports the idea that the cancer developed gradually over time.

Samples obtained by brush cytology consist of loose cells rather than intact tissue, and diagnosis can be challenging — especially in people with primary sclerosing cholangitis, where inflammation itself can make cells appear abnormal. For this reason, a negative brush cytology result does not fully rule out cancer, and additional tests, such as immunohistochemistry or molecular studies, are sometimes used to improve accuracy.

Histologic grade

Histologic grade describes how closely the tumor cells resemble normal bile duct cells under the microscope. For extrahepatic cholangiocarcinoma, grade is based mainly on how much of the tumor forms recognizable glands — a feature of more organized, less aggressive growth. Grade helps predict how the cancer is likely to behave and is one of several factors used to guide treatment.

• Well differentiated — More than 95% of the tumor is made up of well-formed glands. These tumors tend to grow more slowly and are generally less aggressive.
• Moderately differentiated — Between 50% and 95% of the tumor forms glands. This is the most common grade and falls between well and poorly differentiated tumors in its behavior.
• Poorly differentiated — Less than 50% of the tumor forms glands. These tumors are more disorganized, more aggressive, and more likely to spread.

Perineural invasion

Perineural invasion means that cancer cells are found growing around or along nerves. Nerves can act as pathways that allow tumor cells to spread into nearby tissues and beyond the visible edge of the tumor. Perineural invasion is common in extrahepatic cholangiocarcinoma and is an important finding in the pathology report because it is associated with a higher risk of local spread, recurrence after surgery, and a worse overall outcome.

Lymphovascular invasion

Lymphovascular invasion means that cancer cells are found inside small blood vessels or lymphatic channels. These vessels are part of the body’s circulation and can provide a route for cancer cells to reach lymph nodes or distant organs. When lymphovascular invasion is present, it suggests a higher likelihood that cancer has already started to spread and is considered an adverse finding in the pathology report.

Surgical margins

A margin is the edge of the tissue that the surgeon cuts through to remove the tumor. Because the bile duct is a tube, several different margins are usually examined in cholangiocarcinoma — the proximal (upstream) bile duct margin, the distal (downstream) bile duct margin, and the margins of the surrounding soft tissue.

• Negative margin — No cancer cells are seen at the cut edge. This suggests that the tumor was completely removed and is associated with the best chance of long-term survival.
• Close margin — Tumor cells are within a few millimeters of the cut edge but do not reach it. Close margins raise concern for local recurrence, and your surgeon will consider this alongside other features of the tumor.
• Positive margin — Tumor cells are present at the cut edge. A positive margin is associated with a higher risk of recurrence and often prompts consideration of additional treatment, such as chemotherapy or radiation.

Margin status is one of the most important factors in extrahepatic cholangiocarcinoma, because complete surgical removal offers the best chance for cure.

Lymph nodes

Lymph nodes are small immune organs scattered throughout the body. In extrahepatic cholangiocarcinoma, cancer cells can spread through lymphatic channels to nearby (regional) lymph nodes along the bile duct, around the head of the pancreas, and along nearby large blood vessels. During surgery, the surgeon removes these regional lymph nodes for examination under the microscope.

The pathology report will state the total number of lymph nodes examined and the number that contain cancer. Spread to regional lymph nodes is one of the strongest predictors of recurrence and is associated with a worse outcome. Current guidelines recommend examining at least 6 regional lymph nodes to accurately stage the disease.

Biomarker and molecular testing

Biomarker and molecular testing is becoming increasingly important in extrahepatic cholangiocarcinoma, particularly for advanced or recurrent disease, because a growing number of targeted treatments are available when a specific genetic change is found. Current guidelines recommend comprehensive molecular profiling (usually by next-generation sequencing) for anyone with advanced biliary tract cancer. The biomarkers most relevant to extrahepatic cholangiocarcinoma are described below.

HER2

HER2 (also called ERBB2) is a protein that sits on the surface of cells and signals them to grow. Some cholangiocarcinomas — especially those arising in the extrahepatic bile ducts and gallbladder — make too much HER2 or contain extra copies of the HER2 gene. HER2 is first tested by immunohistochemistry (IHC), which measures the amount of protein present, and results are reported on a scale of 0 to 3+. Cases that are IHC 2+ (equivocal) are followed up with in situ hybridization (ISH or FISH) to count the number of HER2 gene copies. A positive result (IHC 3+ or ISH-amplified) makes the tumor eligible for HER2-directed treatments such as zanidatamab, trastuzumab plus pertuzumab, or tucatinib plus trastuzumab.

FGFR2 fusions

FGFR2 is a gene that helps control cell growth. In some cholangiocarcinomas — most often intrahepatic, but occasionally extrahepatic — a segment of the FGFR2 gene is fused to another gene, creating an abnormal fusion that drives the cancer. FGFR2 fusions are usually detected by next-generation sequencing. Tumors with an FGFR2 fusion can be treated with targeted drugs called FGFR inhibitors, including pemigatinib and futibatinib.

IDH1 mutations

IDH1 is an enzyme involved in how cells produce energy. Mutations in the IDH1 gene are most common in intrahepatic cholangiocarcinoma but are occasionally seen in extrahepatic tumors. IDH1 mutations are identified by molecular testing on tumor tissue. A positive result makes the cancer eligible for the targeted drug ivosidenib.

BRAF V600E

BRAF is a gene that, when mutated, drives uncontrolled cell growth. The specific BRAF V600E mutation is uncommon in cholangiocarcinoma (roughly 1 to 5% of cases) but is important because tumors with this mutation can be treated with the combination of dabrafenib and trametinib under a tumor-agnostic approval that applies across cancer types.

NTRK fusions

NTRK fusions are very rare in cholangiocarcinoma, but, when present, make the tumor eligible for highly effective targeted drugs called TRK inhibitors (larotrectinib or entrectinib) under another tumor-agnostic approval.

Mismatch repair (MMR) and microsatellite instability (MSI)

The mismatch repair system is a group of proteins that corrects small errors made during DNA replication. When this system does not function, many small mutations accumulate in the tumor, a state called mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H). MMR deficiency is uncommon in cholangiocarcinoma, but when present, makes the tumor eligible for pembrolizumab under a tumor-agnostic approval. A dMMR or MSI-H result may also indicate Lynch syndrome, an inherited condition that increases the risk of several cancers, and should prompt referral for genetic counseling.

PD-L1

PD-L1 is a protein that tumors can use to hide from the immune system. In cholangiocarcinoma, immunotherapy combinations (durvalumab or pembrolizumab added to chemotherapy) are given as first-line treatment for advanced disease regardless of PD-L1 status, so PD-L1 testing is not required to start treatment. PD-L1 may still be reported as part of broader molecular profiling.

For more information about these and other biomarkers, visit the Biomarkers section.

Pathologic stage (pTNM)

Extrahepatic cholangiocarcinoma is staged using the American Joint Committee on Cancer (AJCC) 8th edition TNM system, which combines information about the tumor (T), regional lymph nodes (N), and distant spread (M). The M category is almost always determined by imaging rather than by pathology. Because perihilar and distal cholangiocarcinoma behave differently, the two tumor types use separate T-stage criteria.

Tumor stage (pT) — perihilar cholangiocarcinoma

• pT1 — Tumor confined to the bile duct, with extension up to the muscle layer or surrounding fibrous tissue.
• pT2a — Tumor extends beyond the wall of the bile duct into the surrounding fat.
• pT2b — Tumor extends into adjacent liver tissue.
• pT3 — Tumor invades branches of the portal vein or hepatic artery on one side.
• pT4 — Tumor invades the main portal vein or its branches on both sides; the common hepatic artery; or second-order bile ducts on both sides, or on one side with involvement of the contralateral portal vein or hepatic artery.

Tumor stage (pT) — distal cholangiocarcinoma

• pT1 — Tumor invades the bile duct wall to a depth of less than 5 mm.
• pT2 — Tumor invades the bile duct wall to a depth of 5 to 12 mm.
• pT3 — Tumor invades the bile duct wall to a depth of more than 12 mm.
• pT4 — Tumor involves the celiac axis, superior mesenteric artery, or common hepatic artery.

Nodal stage (pN)

• pN0 — No cancer is found in regional lymph nodes.
• pN1 — Cancer is found in 1 to 3 regional lymph nodes.
• pN2 — Cancer is found in 4 or more regional lymph nodes.

What is the prognosis?

The outlook for a person with extrahepatic cholangiocarcinoma depends mainly on whether the tumor can be completely removed by surgery, the stage of the disease, and the microscopic features of the tumor. Extrahepatic cholangiocarcinoma is often detected at an earlier stage than intrahepatic cholangiocarcinoma because it tends to block bile flow and cause symptoms sooner, but it remains a serious diagnosis.

For patients who undergo complete surgical resection, five-year survival is approximately 20 to 40% for perihilar tumors and 20 to 30% for distal tumors. Survival is substantially lower when the tumor cannot be completely removed or has already spread, and median survival for advanced disease treated with modern chemotherapy plus immunotherapy is approximately 12 to 15 months.

Pathologic features associated with a worse outcome include:

• Positive surgical margins — Tumor cells at the cut edge; the single strongest modifiable predictor of recurrence.
• Lymph node metastasis — Spread to regional lymph nodes; risk rises further as more nodes are involved.
• High histologic grade — Poorly differentiated tumors behave more aggressively.
• Perineural invasion — Tumor growth along nerves, which often extends well beyond the visible edge of the tumor.
• Lymphovascular invasion — Tumor cells inside small blood vessels or lymphatic channels.
• Higher T stage — Deeper invasion of the bile duct wall or involvement of major blood vessels.
• Larger tumor size — Larger tumors are more likely to recur after surgery.

A minority of tumors show a papillary growth pattern, which tends to carry a better outlook than the typical gland-forming type.

What happens after the diagnosis?

Care for extrahepatic cholangiocarcinoma is usually coordinated by a multidisciplinary team that includes a hepatobiliary surgeon, a medical oncologist, a radiation oncologist, an interventional radiologist, and a gastroenterologist. Treatment depends on where the tumor is located along the bile duct, how far it has spread, and the patient’s overall health.

When the tumor can be removed surgically, the procedure depends on the location. Perihilar tumors typically require removal of the affected bile duct along with part of the liver and, in some cases, part of the pancreas. Distal tumors are usually treated with a procedure called pancreaticoduodenectomy (the Whipple operation), which removes the head of the pancreas, part of the small intestine, the gallbladder, and part of the bile duct. After surgery, chemotherapy with capecitabine is often given to reduce the risk of recurrence, and radiation therapy may be added in selected cases.

When surgery is not possible, first-line treatment for advanced extrahepatic cholangiocarcinoma is typically a combination of chemotherapy (gemcitabine and cisplatin) with immunotherapy (durvalumab or pembrolizumab). Patients whose tumors carry specific genetic changes — such as HER2 amplification, FGFR2 fusions, IDH1 mutations, BRAF V600E mutations, or NTRK fusions — may be eligible for targeted therapies either upfront or after initial treatment. Relief of bile duct blockage with a stent, placed during ERCP, is often needed to treat jaundice and prevent infection. Follow-up after treatment usually includes regular imaging and blood tests, including the tumor marker CA 19-9.

Questions to ask your doctor

• Where exactly is my tumor located in the bile duct — perihilar or distal?
• What is the histologic grade of my tumor?
• Is perineural invasion or lymphovascular invasion present in my pathology report?
• What is the pathologic stage (pTNM) of my cancer?
• If I had surgery, were the surgical margins negative, close, or positive?
• How many lymph nodes were examined, and how many contained cancer?
• Can the tumor be surgically removed, or has it spread too far?
• Has my tumor been tested for HER2, FGFR2 fusions, IDH1 mutations, BRAF, NTRK fusions, and mismatch repair status?
• Are any of my molecular test results actionable with a targeted treatment?
• Am I a candidate for a clinical trial?
• Will I need chemotherapy, immunotherapy, radiation therapy, or a combination after surgery?
• Do I need a stent to relieve bile duct blockage, and how will that be managed?
• What is the plan for follow-up imaging and CA 19-9 testing?
• Do I have an underlying liver or bile duct condition (such as primary sclerosing cholangitis) that needs to be managed at the same time?